2-[¹⁸F]fluoro-2-deoxy-d-glucose PET in Brain Tumors

Area of Science:

• Nuclear medicine imaging
• Oncology
• Neuroscience

Background:

• 2-[18F]fluoro-2-deoxy-d-glucose (18F FDG) PET is a key imaging modality in neuro-oncology.
• It provides essential metabolic information for both adult and pediatric brain tumors.
• 18F FDG PET plays a significant role in the diagnosis, staging, prognostic assessment, and treatment monitoring of primary central nervous system lymphomas.

Purpose of the Study:

• To highlight the utility of 18F FDG PET in neuro-oncology.
• To discuss its applications in brain tumor characterization, diagnosis, and management.
• To address the challenges and benefits of using 18F FDG PET in brain tumor imaging.

Main Methods:

• Positron Emission Tomography (PET) imaging using the radiotracer 2-[18F]fluoro-2-deoxy-d-glucose (18F FDG).
• Analysis of metabolic activity in brain tumors.
• Comparison of tumor uptake versus physiologic uptake in normal brain tissue.

Main Results:

• 18F FDG PET provides valuable metabolic information in adult and pediatric brain tumors.
• It is crucial for diagnosis, staging, prognostic assessment, and treatment monitoring of primary central nervous system lymphomas.
• Despite reduced tumor-to-background contrast in some gliomas due to high physiologic uptake, 18F FDG PET can characterize tumor aggressiveness, guide biopsies, and detect residual or recurrent disease.

Conclusions:

• 18F FDG PET is a valuable tool in neuro-oncology for various brain tumors.
• Its ability to assess metabolic activity aids in clinical decision-making.
• Careful interpretation is needed due to physiologic uptake, but its role in diagnosis and monitoring is significant.